Search Result

Isoforms Recommended:	BRaf

Results for "

B-Raf

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Raf (90) Akt (1) Apoptosis (14) Aurora Kinase (1) Autophagy (13) Bcr-Abl (2) c-Kit (2) c-Met/HGFR (2) CDK (1) Discoidin Domain Receptor (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (5) Ephrin Receptor (1) ERK (4) Ferroptosis (5) FGFR (2) FLT3 (6) Isotope-Labeled Compounds (3) MEK (3) Molecular Glues (1) Oxidative Phosphorylation (2) p38 MAPK (6) Parasite (2) PDGFR (2) PERK (2) PROTACs (6) Ras (1) RET (4) Ribosomal S6 Kinase (RSK) (2) Small Interfering RNA (siRNA) (3) Src (3) VEGFR (11)
By Research Areas:	Cancer (96) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (2)

By Targets:

Raf (90)

Akt (1)

Apoptosis (14)

Aurora Kinase (1)

Autophagy (13)

Bcr-Abl (2)

c-Kit (2)

c-Met/HGFR (2)

CDK (1)

Discoidin Domain Receptor (1)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (5)

Ephrin Receptor (1)

ERK (4)

Ferroptosis (5)

FGFR (2)

FLT3 (6)

Isotope-Labeled Compounds (3)

MEK (3)

Molecular Glues (1)

Oxidative Phosphorylation (2)

p38 MAPK (6)

Parasite (2)

PDGFR (2)

PERK (2)

PROTACs (6)

Ras (1)

RET (4)

Ribosomal S6 Kinase (RSK) (2)

Small Interfering RNA (siRNA) (3)

Src (3)

VEGFR (11)

By Research Areas:

Cancer (96)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (2)

104

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Raf

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-142820

B-Raf IN 5	Raf	Cancer
B-Raf IN 5 (compound 3b) is a potent inhibitor of protein kinase *B-Raf* with an IC₅₀ of 2.0 nM. B-Raf IN 5 is devoid of binding to the secondary target PXR and resists rapid metabolism. B-Raf IN 6 has the potential for the research of cancer disease .

HY-142830

B-Raf IN 6	Raf	Cancer
B-Raf IN 6 (compound 2c) is a potent inhibitor of protein kinase *B-Raf* with an IC₅₀ of 1.7 nM. B-Raf IN 6 is devoid of binding to the secondary target PXR and resists rapid metabolism. B-Raf IN 6 has the potential for the research of cancer disease .

HY-147854

B-Raf IN 9	Raf Apoptosis	Cancer
B-Raf IN 9 (compound 8b) is a potent *B-Raf* inhibitor, with an IC₅₀ of 24.79 nM. B-Raf IN 9 induces apoptosis and shows cell cycle arrest at G2/M phase. B-Raf IN 9 exhibits potent antitumor activity against human prostate cancer PC-3 cell line, with an IC₅₀ of 7.83 µM .

HY-147853

B-Raf IN 8	Raf	Cancer
B-Raf IN 8 (compound 7g) is a potent *B-Raf* inhibitor, with an IC₅₀ of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC₅₀ values of 9.78, 13.78, 18.52 and 29.85 µM .

HY-147852

B-Raf IN 7	Raf	Cancer
B-Raf IN 7 (compound 6a) is a potent *B-Raf* inhibitor, with an IC₅₀ of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC₅₀ values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM .

HY-77113

B-Raf IN 11	Raf	Cancer
B-Raf IN 11 (ZINC72115182) is a selective B-Raf ^V600E inhibitor (IC₅₀=76 nM), shows selectivity for B-Raf ^V600E over B-Raf ^WT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research

HY-153603

B-Raf IN 15	Raf	Cancer
B-Raf IN 15 (Compound 7) is a *BRAF* inhibitor. B-Raf IN 15 inhibits BRAF WT and BRAF V600E with IC₅₀s of 2.0 and 0.8 μM. B-Raf IN 15 can be used for the research of cancer .

HY-18227

B-Raf IN 1

Raf Cancer

B-Raf IN 1 is a potent and selective B-Raf kinase inhibitor with an IC₅₀ of 24 nM.
HY-156590

B-Raf IN 16

Raf Cancer

B-Raf IN 16 (Compound I) is a BRAF inhibitors that belongs a cyclic iminopyrimidine derivative. B-Raf IN 16 can be used for cancer research .
HY-150250

B-Raf IN 13

Raf Cancer

B-Raf IN 13 is a BRAF inhibitor with an IC₅₀ of 3.55 nM in BRAF V600E enzyme assay. B-Raf IN 13 has anticaner effects (WO2020261156A1, Example 74) .
HY-145120

B-Raf IN 2

Raf Cancer

B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer .

B-Raf IN 1	Raf	Cancer
B-Raf IN 1 is a potent and selective *B-Raf* kinase inhibitor with an IC₅₀ of 24 nM.

B-Raf IN 16	Raf	Cancer
B-Raf IN 16 (Compound I) is a *BRAF* inhibitors that belongs a cyclic iminopyrimidine derivative. B-Raf IN 16 can be used for cancer research .

B-Raf IN 13	Raf	Cancer
B-Raf IN 13 is a BRAF inhibitor with an IC₅₀ of 3.55 nM in BRAF V600E enzyme assay. B-Raf IN 13 has anticaner effects (WO2020261156A1, Example 74) .

B-Raf IN 2	Raf	Cancer
B-Raf IN 2 is a potent and selective *BRAF* inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer .

HY-158027

B-Raf IN 17	Raf VEGFR FGFR	Cancer
B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAF_WT, VEGFR-2, and FGFR-1 in A375 cell line, with IC₅₀ values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer .

HY-153914

B-Raf IN 14

Raf Cancer

B-Raf IN 14 (Comp 25) is a BRAF inhibitor with IC₅₀ value of 11.08 μM, which can be used in cancer-related research .
HY-148059

Uplarafenib

B-Raf IN 10
Raf Cancer

Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC₅₀ between 50 and 100 nM. Uplarafenib shows antitumor activity .
HY-10247

BRAF inhibitor

1 Publications Verification

Raf Cancer

BRAF inhibitor is a B-Raf inhibitor extracted from patent WO/2011103196 A1, Compound P-0850.

B-Raf IN 14	Raf	Cancer
B-Raf IN 14 (Comp 25) is a BRAF inhibitor with IC₅₀ value of 11.08 μM, which can be used in cancer-related research .

Uplarafenib B-Raf IN 10	Raf	Cancer
Uplarafenib (B-Raf IN 10) (Compound C09) is a *BRAF* inhibitor with an IC₅₀ between 50 and 100 nM. Uplarafenib shows antitumor activity .

BRAF inhibitor 1 Publications Verification	Raf	Cancer
BRAF inhibitor is a *B-Raf* inhibitor extracted from patent WO/2011103196 A1, Compound P-0850.

HY-RS01588

BRAF Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
BRAF Human Pre-designed siRNA Set A contains three designed siRNAs for BRAF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

BRAF Human Pre-designed siRNA Set A BRAF Human Pre-designed siRNA Set A

HY-RS01589

Braf Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Braf Mouse Pre-designed siRNA Set A contains three designed siRNAs for Braf gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Braf Mouse Pre-designed siRNA Set A Braf Mouse Pre-designed siRNA Set A

HY-RS01590

Braf Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Braf Rat Pre-designed siRNA Set A contains three designed siRNAs for Braf gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Braf Rat Pre-designed siRNA Set A Braf Rat Pre-designed siRNA Set A

HY-146442

BRAF V600E/CRAF-IN-1	Raf	Cancer
BRAF V600E/CRAF-IN-1 (Compound 8b) is a potent inhibitor of BRAF ^V600E/CRAF. BRAF V600E/CRAF-IN-1 triggers apoptosis and cell cycle arrest at G0/G1 phase in HCT-116 colon cancer cell. BRAF V600E/CRAF-IN-1 has the potential for the research of cancer diseases .

HY-146443

BRAF V600E/CRAF-IN-2	Raf	Cancer
BRAF V600E/CRAF-IN-2 (Compound 9c) is a potent inhibitor of BRAF ^V600E/CRAF with IC₅₀s of 0.888 and 0.229 μM, respectively. BRAF V600E/CRAF-IN-2 triggers apoptosis and cell cycle arrest at G0/G1 phase in HCT-116 colon cancer cell. BRAF V600E/CRAF-IN-2 has the potential for the research of cancer diseases .

HY-111758

*PROTAC B-Raf* degrader 1**	PROTACs Raf	Cancer
PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of *B-Raf* based on Cereblon ligand with anti-cancer activity .

HY-130617

Pomalidomide-amido-C1-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758). PROTAC B-Raf degrader 1 has anti-cancer activity .

HY-16063

ARQ-736

Raf Cancer

ARQ-736 is a potent and selective B-RAF inhibitor that plays an important role in cancer study .

ARQ-736	Raf	Cancer
ARQ-736 is a potent and selective B-RAF inhibitor that plays an important role in cancer study .

HY-156554

Raf inhibitor 3	Raf	Cancer
Raf inhibitor 3 (Example 30) is a Raf inhibitor. Raf inhibitor 3 inhibits B-Raf and C-Raf with IC₅₀ values less than 15 nM. Raf inhibitor 3 can be used for research of cancers .

HY-14177A

Raf inhibitor 1 dihydrochloride	Raf	Cancer
B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-12661A

AMG PERK 44 3 Publications Verification	PERK Autophagy	Cancer
AMG PERK 44 is an orally active and highly selective PERK inhibitor with an IC₅₀ of 6 nM. AMG PERK 44 has 1000-fold and 160-fold selectivity over GCN2 (IC₅₀=7300 nM) and B-Raf (IC₅₀ >1000 nM), respectively. AMG PERK 44 induces autophagy .

HY-15198

KG5	Raf PDGFR FLT3 c-Kit	Cancer
KG5 is an orally active dual PDGFRβ and *B-Raf* allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities .

HY-14177

Raf inhibitor 1 3 Publications Verification	Raf	Cancer
Raf inhibitor 1 is a potent Raf kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-109080

Belvarafenib 1 Publications Verification HM95573; GDC-5573; RG6185	Raf	Cancer
Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC₅₀s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF ^v600E and C-RAF respectively .

HY-50864

GDC-0879

3 Publications Verification

Raf Cancer

GDC-0879 is a potent and selective B-Raf inhibitor with an IC₅₀ of 0.13 nM.
HY-12787

L-779450

1 Publications Verification

Raf Autophagy Cancer

L-779450 is a potent and selective B-Raf kinase inhibitor with a K_d of 2.4 nM.

GDC-0879 3 Publications Verification	Raf	Cancer
GDC-0879 is a potent and selective *B-Raf* inhibitor with an IC₅₀ of 0.13 nM.

L-779450 1 Publications Verification	Raf Autophagy	Cancer
L-779450 is a potent and selective *B-Raf* kinase inhibitor with a K_d of 2.4 nM.

HY-115933

*EGFR/BRAF-IN-1*	EGFR Raf	Cancer
EGFR/BRAF-IN-1 (compound 21), a 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivative, is a potent *EGFR/BRAF* inhibitor with an IC₅₀ of 45 nM for BRAF ^V600E. EGFR/BRAF-IN-1 inhibits cancer cell proliferation (GI₅₀=35 nM). EGFR/BRAF-IN-1 shows good antioxidant activity .

HY-51424

PLX-4720 5+ Cited Publications	Raf	Cancer
PLX-4720 is a potent and selective inhibitor of B-Raf ^V600E with IC₅₀ of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-Raf ^V600E than wild-type B-Raf.

HY-126298

RAF mutant-IN-1	Raf	Cancer
RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC₅₀ values of 21 nM, 30 nM and 392 nM for C-RAF ^340D/Y341D, B-RAF ^V600E and B-RAF ^WT, respectively .

HY-146492

*VEGFR-2/BRAF-IN-2*	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual VEGFR-2 and *BRAF* kinases inhibitor with IC₅₀ values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase .

HY-12291

HG6-64-1 HMSL 10017-101-1	Raf	Cancer
HG6-64-1 is a potent and selective *B-Raf* inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC₅₀ of 0.09 μM on B-raf V600E transformed Ba/F3 cells.

HY-10966

SB-590885 4 Publications Verification	Raf	Cancer
SB-590885 is a potent B-Raf* inhibitor* with K_i of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.

HY-146491

*VEGFR-2/BRAF-IN-1*	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-1 (Compound 4b) is a dual VEGFR-2 and *BRAF* kinases inhibitor with IC₅₀ values of 0.049, 0.063 and 0.005 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-1 induces apoptosis and arrests the cell cycle mainly in the G1/S phase .

HY-137488

*PROTAC BRAF-V600E degrader-2*	PROTACs Raf	Cancer
PROTAC BRAF-V600E degrader-2 (compound 12) is a potent *BRAF-V600E* degrader with K_ds of 14.4 nM and 9.5 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-2 selectively degraded the kinase domain of BRAF-V600E but not the wild-type BRAF. PROTAC BRAF-V600E degrader-2 inhibits melanoma cell growth .

HY-137487

*PROTAC BRAF-V600E degrader-1*	PROTACs Raf	Cancer
PROTAC BRAF-V600E degrader-1 is a potent PROTAC BRAF-V600E degrader with K_d value of 2.4 nM and 2 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-1 degrades BRAF-V600E via the ubiquitin-proteasome system (UPS). PROTAC BRAF-V600E degrader-1 can inhibit melanoma cell growth .

HY-12846

CCT196969

Raf Cancer

CCT196969 is a pan-Raf inhibitor, which inhibits B-Raf, BRaf ^V600E and CRAF with IC₅₀s of 0.1, 0.04, and 0.01 μM, respectively.

CCT196969	Raf	Cancer
CCT196969 is a pan-Raf inhibitor, which inhibits *B-Raf, BRaf* ^V600E and CRAF with IC₅₀s of 0.1, 0.04, and 0.01 μM, respectively.

HY-155736

MAPK-IN-2	p38 MAPK EGFR Raf CDK c-Met/HGFR	Cancer
MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 inhibits cancer cell proliferation among serval cancer cell lines, and suppresses MAPK pathway with potant efficacy (EGFR ^WT IC₅₀=281 nM, c-MET IC₅₀=205 nM, B-RAF ^WT IC₅₀=112 nM, and CDK4/6 IC₅₀=95 and 184 nM, respectively). MAPK-IN-2 even shows a remarkable potency against mutated EGFR and B-RAF (EGFR ^T790M IC₅₀=69 nM and B-RAF ^V600E IC₅₀=83 nM) .

HY-14979A

ML786 dihydrochloride	Raf Bcr-Abl Discoidin Domain Receptor VEGFR RET Ephrin Receptor	Cancer
ML786 dihydrochloride is a potent and orally bioavailable Raf inhibitor, with IC₅₀s of 2.1, 4.2, and 2.5 nM for ^V600EΔB-Raf, wt B-Raf, and C-Raf, respectively. ML786 dihydrochloride also inhibits Abl-1, DDR2, EPHA2, KDR, and RET (IC₅₀=<0.5, 7.0, 11, 6.2, 0.8 nM). ML786 dihydrochloride can be used for the research of cancers .

HY-14660

Dabrafenib 40+ Cited Publications GSK2118436A; GSK2118436	Raf	Cancer
Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC₅₀s of 5 nM and 0.6 nM for C-Raf and B-Raf ^V600E, respectively .

HY-11004

AZ 628

5+ Cited Publications

Raf Apoptosis Cancer

AZ 628 is a pan-Raf kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.

AZ 628 5+ Cited Publications	Raf Apoptosis	Cancer
AZ 628 is a pan-Raf kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for *B-Raf, B-RafV600E, and c-Raf-1*, respectively.

HY-111940

LUT014	Raf	Inflammation/Immunology
LUT014 is a *B-Raf* inhibitor with an IC₅₀ of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 .

HY-10201S1

Sorafenib-d4 Bay 43-9006-d₄	Raf VEGFR FLT3 Ferroptosis Autophagy Apoptosis	Cancer
Sorafenib-d₄ is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-109080A

Belvarafenib TFA HM95573 TFA; GDC-5573 TFA; RG6185 TFA	Raf	Cancer
Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC₅₀s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv ^600E and C-RAF respectively .

HY-12057

Vemurafenib 60+ Cited Publications PLX4032; RG7204; RO5185426	Raf Autophagy	Cancer
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of *B-RAF* kinase, with IC₅₀s of 31 and 48 nM for RAF ^V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-10201S

Sorafenib-d3 Donafenib; Bay 43-9006-d₃	Raf VEGFR FLT3 Ferroptosis Autophagy Apoptosis	Cancer
Sorafenib-d₃ (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3634

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	Others
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

Cat. No.	Product Name	Chemical Structure

HY-10201S

Sorafenib-d3
Sorafenib-d₃ (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .

HY-10201S1

Sorafenib-d4

Sorafenib-d₄ is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-12057S

Vemurafenib-d5
Vemurafenib-d₅ is the deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].

HY-12057S1

Vemurafenib-d7
Vemurafenib-d₇ is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].

HY-51424S

PLX-4720-d7
PLX-4720-d₇ is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of B-RafV600E with an IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf[1][2].

HY-10201S2

Sorafenib-13C,d3

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

HY-15605S

Encorafenib-13C,d3
Encorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Encorafenib. Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks